FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:989-991 September 27, 2001 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Israel, E. Related Article by Smith, M. R. PubMed Citation

In this issue of the Journal, two groups of investigators report that the treatment of a primary medical condition resulted in accelerated bone loss.^1,2 In one study, by Smith et al.,¹ men with prostate cancer who were treated with leuprolide had rapid bone loss, which was prevented in a similar group of men by the addition of pamidronate therapy. In the other study, by Israel et al.,² premenopausal women taking inhaled glucocorticoids for the treatment of asthma lost more bone mass than women who were not taking inhaled glucocorticoids. What mechanisms do these two agents of bone loss share?

Decreased . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Gluck, O., Colice, G. (2004). Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases. Chest 125: 1859-1876 [Abstract] [Full Text]  
• Dubois, E. F., Roder, E., Dekhuijzen, P. N. R., Zwinderman, A. E., Schweitzer, D. H. (2002). Dual Energy X-ray Absorptiometry Outcomes in Male COPD Patients After Treatment With Different Glucocorticoid Regimens*. Chest 121: 1456-1463 [Abstract] [Full Text]